Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +42

Bristol-Myers Squibb stock holds firm as ORM-6151 setback meets solid Q2 2026 margins

AI-generated analysis

📉 BMY shares closed at USD 62.84 on September 17, 2026, trading 8.4% below the 52-week high but significantly above the low.

💰 Q2 2026 revenue increased by 5.7% with a robust profit margin of 25.57%, demonstrating strong operational efficiency.

🚫 The company discontinued development of ORM-6151 and returned rights to Orum Therapeutics after reviewing Phase 1 data.

💸 BMY had previously committed USD 100 million to the ORM-6151 degrader-antibody conjugate program before pulling back.

📊 The stock trades at a forward P/E of 9.58x, which is substantially lower than the industry average of 18.01x.

🚀 Shares have gained 16.5% year-to-date, outperforming the broader pharmaceutical industry's 5.7% growth rate.

📈 Analyst consensus estimates for 2026 earnings per share rose to USD 6.91 from USD 6.34 over the past 60 days.

🗓️ The next earnings report is scheduled for release on October 29, 2026.

🏢 BMY maintains a market capitalization of approximately USD 129.46 billion as of September 18, 2026.

⚖️ The stock currently holds a Zacks Rank of 3 (Hold), reflecting a balanced analyst stance on valuation and pipeline.

Bullish Signals
  • Bristol-Myers Squibb delivered strong Q2 2026 financial results with revenue growth of 5.7% and a profit margin of 25.57%, supporting the stock price.
  • The company trades at a significant valuation discount to the industry average, with a forward P/E ratio of 9.58x compared to an industry average of 18.01x.
  • Shares have appreciated 16.5% year-to-date, significantly outperforming the broader pharmaceutical sector's 5.7% growth.
  • Analyst consensus estimates for 2026 earnings per share have increased to USD 6.91, indicating constructive expectations for future performance.
  • The stock is trading in the upper half of its 52-week range, suggesting investor confidence despite specific pipeline setbacks.
Risk Factors
  • Bristol-Myers Squibb discontinued development of ORM-6151 and returned rights to Orum Therapeutics after reviewing early Phase 1 clinical data.
  • The company ended a program where it had previously committed USD 100 million, reflecting a strategic pivot following the review of pipeline assets.
Full Analysis
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, trading approximately 8.4% below their 52-week high but well above the low. The company reported strong second-quarter 2026 financial performance with revenue rising 5.7% year-over-year and achieving a profit margin of 25.57%. These solid operational metrics provided a quantitative counterweight to recent negative developments in its drug development pipeline, helping to stabilize investor sentiment despite the halt on specific assets. The primary headwind for BMY involves the discontinuation of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics. After reviewing early Phase 1 clinical data, Bristol-Myers Squibb decided to return development rights to the biotech partner, ending a program where it had previously committed USD 100 million. While this setback negatively impacted Orum Therapeutics' stock price by over 33%, analysts view the impact on BMY as contained due to the depth of its broader oncology and immunology portfolios. From a valuation perspective, BMY trades at a significant discount to the broader large-cap pharmaceutical industry, with a forward price-to-earnings ratio of 9.58 times compared to an industry average of 18.01 times. The stock has gained 16.5% year-to-date, outpacing the broader industry's 5.7% growth, suggesting investors have already rewarded the company for its operational delivery. Analyst consensus remains constructive with rising earnings estimates for 2026 and 2027, though the Zacks Rank is currently a 'Hold' pending further pipeline progress. Looking ahead, the next scheduled earnings release is set for October 29, 2026. With a market capitalization of approximately USD 129.46 billion, BMY remains a core constituent of the S&P 500 Health Care sector. Investors are weighing the near-term pipeline volatility against the company's attractive valuation and strong mid-single-digit revenue growth, positioning the stock in the upper half of its 52-week trading range.